|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | MDS Inc., a Canadian health-services company. |
|---|---|
| Transferring Party | Molecular Devices Corp., a provider of high-performance measurement tools for high-content screening, cellular analysis and biochemical testing. |
| Sector | Diagnostics |
| Date | March 28, 2007 |
| Analysis Strengthen MDS' position as one of the top global providers of life sciences solutions, with high content screening, cellular and biochemical testing for leading drug discovery and life sciences laboratories in pharmaceutical, biotechnology, academic and government institutions. Deal value -- $615m, on sales of $185.3 (3.3x) and $38.0 of EBITDA (16.2x). MDS expects costs savings of $10-12m. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |